ArticleSpringerPlus2013
In -silico molecular docking analysis of prodigiosin and cycloprodigiosin as COX-2 inhibitors.
Article in SpringerPlus, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 57 citations in OpenAlex.
- Toxicity and Anti-inflammatory Effects ofAnti-inflammatory & anti-allergy agents in medicinal chemistry · 2025Article
- Prodigiosin/celecoxib-loaded into zein/sodium caseinate nanoparticles as a potential therapy for triple negative breast cancer.Scientific reports · 2024Article
- The Golgi stacking protein GRASP55 is targeted by the natural compound prodigiosin.Cell communication and signaling : CCS · 2023Article
- Rise of the natural red pigment 'prodigiosin' as an immunomodulator in cancer.Cancer cell international · 2022Review
- Prodigiosin: a promising biomolecule with many potential biomedical applications.Bioengineered · 2022Review
- Optimization of Carotenoids Production fromJournal of fungi (Basel, Switzerland) · 2022Article
- Utilization of Cassava Wastewater for Low-Cost Production of Prodigiosin viaMolecules (Basel, Switzerland) · 2021Article
- Bioprocessing of Marine Chitinous Wastes for the Production of Bioactive Prodigiosin.Molecules (Basel, Switzerland) · 2021Article
- Bioengineering of Anti-Inflammatory Natural Products.ChemMedChem · 2021Review
- Prodigiosin Modulates the Immune Response and Could Promote a Stable Atherosclerotic Lession in C57bl/6International journal of molecular sciences · 2020Article
- An Indonesian Marine Bacterium,ACS omega · 2020Article
- Computational and Biological Comparisons of Plant Steroids as Modulators of Inflammation through Interacting with Glucocorticoid Receptor.Mediators of inflammation · 2019Article
- Inhibitory Growth of Oral Squamous Cell Carcinoma Cancer via Bacterial Prodigiosin.Marine drugs · 2017Article
- Natural Compounds from Herbs that can Potentially Execute as Autophagy Inducers for Cancer Therapy.International journal of molecular sciences · 2017Review
- Phosphatidylinositide 3-kinase inhibition: A new potential target for the treatment of polycystic ovarian syndrome.Pharmaceutical biology · 2016Article
- Molecular docking analysis of known flavonoids as duel COX-2 inhibitors in the context of cancer.Bioinformation · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prodigiosin and cycloprodigiosin are tripyrrole red pigmented compounds with medical importance for their anticancer property. In the present investigation, molecular docking studies were performed for both prodigiosin and cycloprodigiosins to evaluate the in- silico anti-inflammatory activity against Cycloxigenase-2 (COX-2) protein as model compound and the data compared with rofecoxib and celcoxid. Cycloprodigiosin showed higher initial potential, initial RMS gradient and potential energy values compared to prodigiosin. Analysis of COX-2 protein and ligand binding revealed that cyclprodigiosin interacted with COX-2 protein amino acid residues of Tyr(324), Phe(487) and Arg(89) while prodigiosin interaction was observed with two amino acids i.e. Leu(321) and Tyr(324). The computational ligand binding interaction suggested > 45% higher fitness score value for prodigiosin to that of cycloprodigiosin with COX-2 protein while the standard compounds rofecoxib and celecoxid revealed fitness score of 44 and 62, respectively. The prodigiosin ligand revealed the best fitness score compared with the standard drug rofecoxib suggesting the prodigiosin could be effective as the potential inhibitor compound against COX-2 protein and can be evaluated as anti-inflammatory drug molecule using clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.